HR Execs on the Move

Xeris Pharmaceuticals

www.xerispharma.com

 
It`s all about the experience. Everything we do is about simplifying and making things better and easier. It`s about making a difference in people`s lives.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.xerispharma.com
  • 180 North LaSalle Street Suite 1600
    Chicago, IL USA 60601
  • Phone: 844.445.5704

Executives

Name Title Contact Details
Rochelle Lund
Sr. Director, Talent Acquisition Profile
Steven Pieper
Chief Financial Officer Profile
Barry Deutsch
Chief Financial Officer Profile
Paul Edick
President and Chief Executive Officer Profile

Similar Companies

Axcan Pharma Inc

Axcan Pharma Inc is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Galera Therapeutics

Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

Institute for Therapy through the Arts

The Institute for Therapy through the Arts offers art therapy, music therapy, dance therapy, and drama therapy in Evanston, IL 60201 and Chicagoland.

DUSA Pharmaceuticals

DUSA Pharmaceuticals is a Wilmington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.